Phosphazole compounds

• US 6,069,132 A
• Filed: 08/13/1997
• Issued: 05/30/2000
• Est. Priority Date: 08/14/1996
• Status: Expired due to Fees

• Current Assignee: Aronex Pharmaceuticals Inc. (Agenus Inc.)
• Original Assignee: Aronex Pharmaceuticals Inc. (Agenus Inc.)
• Inventors: Revanker, Ganapathi R.
• Primary Examiner(s): Crane, L. Eric
• Application Number:
  US08/910,291
• Time in Patent Office: 1,021 Days
• Field of Search: 514/43, 514/47, 514/261, 536/27.13, 536/27.14, 536/27.2, 544/264
• US Class Current: 514/43
• CPC Class Codes: C07F 9/6584 having one phosphorus atom as ring hetero atom
• CPC Class Codes: C07H 19/00 Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof

Abstract

A class of substituted and unsubstituted nucleo-base analogs and related azoles, designated as "phosphazoles," is disclosed, certain preferred embodiments having the basic structure of ##STR1## Also disclosed are methods of making and using the new compounds.

Claims

1. A pyrimidophosphazole having a five membered heterocyclic ring, the five membered heterocyclic ring having a nitrogen atom and a trivalent phosphorus atom and the pyrimidophosohazole ring system being of the general structure:

##STR59## wherein A is selected from the group consisting of H, NH₂, O or Cl;

B is selected from the group consisting of H, NH₂, or Q; and

R is selected from the group, consisting of H,

--(CH₂)₄ CH₃,

--(CH₂)₅ CH₃,

--CH₂ CH═

CH₂,

--CH₂ CH═

CHCH₂ CH₃ (cis and trans), ##STR60## --CH₂ CH═

C(CH₃)₂, --(CH₂)₃ CH₂ OH,

--CH₂ CH═

CHCH₂ OH,

--CH₂ CH═

C(CH₃)₂, ##STR61##

2. A compound of claim 1 wherein A is NH₂ and B is H.

3. A compound of claim 1 wherein A is O and B is NH₂.

4. A compound of claim 1 wherein A is O and B is H.

5. A compound of claim 1 wherein A is O and B is O.

11. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.

6. A compound having the structure wherein

A is selected from the group consisting of H, NH₂, O, S or Cl;

B is selected from the group consisting of H NH₂, or O; and

R is selected from the group consisting of H,

--(CH₂)₄ CH₃,

--(CH₂)₅ CH₃,

--CH₂ CH═

CH₂,

--CH₂ CH═

CHCH₂ CH₃ (cis and trans), ##STR62## --CH₂ CH═

C(CH₃)₂, --(CH₂)₃ CH₂ OH,

--CH₂ CH═

CHCH₂ OH,

--CH₂ CH═

C(CH)₂, ##STR63##

7. A compound of claim 6 wherein A is NH₂, and B is H.

8. A compound of claim 6 wherein A is O and B is NH₂.

9. A compound of claim 6 wherein A is O and B is H.

10. A compound of claim 6 wherein A is O and B is O.

12. A pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier.